Clinical Utility of Fasting Plasma Glucose and Hemoglobin A1C (HbA1C) for the Prediction of Type 2 Diabetes Mellitus Diagnosed by Oral Glucose Tolerance Testing in Cirrhotic Patients with Impaired Fasting Plasma Glucose
DOI:
https://doi.org/10.31584/psumj.2024269189Keywords:
cirrhosis, diabetes mellitus, fasting plasma glucose, hemoglobin A1c, oral glucose tolerance testAbstract
Objective: Use of fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) levels has been ineffective in diagnosing diabetes in cirrhotic patients. The aim of this study was to determine the prevalence and optimal cut-off levels of FPG and HbA1c for effective prediction of type 2 diabetes mellitus (T2DM) as definitely diagnosed by the 75-gram oral glucose tolerance test (75-g OGTT) in cirrhotic patients with impaired fasting plasma glucose (IFG).
Material and Methods: This single-center, cross-sectional study conducted in Nan Hospital included cirrhotic patients with IFG that were diagnosed as T2DM or non-T2DM via 75-g OGTT. The clinical factors associated with the presence of T2DM were investigated using univariate and multivariate regression models.
Results: T2DM was diagnosed according to 75-g OGTT in 55 of the 103 participants (53.40%); impaired glucose tolerance (IGT) was diagnosed in 22.33%, and normal OGTT results were found in 24.27%. An FPG level of ≥104.5 mg/dL and an HbA1c level of ≥5.25% were found to be the optimal cut-off levels for the prediction of T2DM. The FPG level had a sensitivity of 76.4%, 95% confidence interval (CI) [63.0%, 86.8%], and a specificity of 37.5%; 95% CI [24.0%, 52.6%]. HbA1c levels had a sensitivity of 67.3%; 95% CI [53.3%, 79.3%] and a specificity of 37.5%; 95% CI [24.0%, 52.6%]. Hepatitis C virus (HCV) infection, high Child-Pugh score, and high level of FPG before the 75-g OGTT testing were significantly associated with T2DM.
Conclusion: More than half of the cirrhotic patients with IFG had T2DM diagnosed by 75-g OGTT. An FPG level of ≥104.5 mg/dL and an HbA1c level of ≥5.25% were found to be the optimal cut-off levels for the prediction of the presence of T2DM in those with cirrhosis and IFG.
References
Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967;2:1051-6.
García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Villarreal-Pérez JZ, Maldonado-Garza HJ. Hepatogenous diabetes: is it a neglected condition in chronic liver disease? World J Gastroenterol 2016;22:2869-74.
Yolanta T. Kruszynskaph, Ilipd Hom, Neil Mcintyre. Relationship between Insulin Sensitivity, Insulin Secretion and Glucose Tolerance in Cirrhosis. Hepatology 1991;14:101-11.
Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002;17:677–81.
Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009;15:280–8.
Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994;20:119–25.
Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006;101:70–5.
Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E, et al. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol 2014;109:1020–5.
Berman K, Tandra S, Forssell K, Vuppalanchi R, Burton J, Nguyen J, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011;9:254–9.
Quintana JOJ, García-Compean D, González JAG, Perez JZV, Gonzalez FJL, Espinosa LEM, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011;10:56–62.
Liu TL, Trogdon J, Weinberger M, Fried B, Barritt AS. Diabetes is associated with clinical decompensation events in patients with cirrhosis. Dig Dis Sci 2016;61:3335–45.
Ahn SB, Powell EE, Russell A, Hartel G, Irvine KM, Moser C, et al. Type 2 Diabetes: a risk factor for hospital readmissions and mortality in Australian patients with cirrhosis. Hepatol Commun 2020;4:1279–92.
Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int 2016;36:936–48.
Jeon HK, Kim MY, Baik SK. Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage. Dig Dis Sci 2013:3335–41.
El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–8.
Bartoli E, Fra GP, Carnevale Schianca GP. The oral glucose tolerance test (OGTT) revisited. Eur J Intern Med 2011;22:8–12.
Hoyer A, Rathmann W, Kuss O. Utility of HbA1c and fasting plasma glucose for screening of Type 2 diabetes: a meta-analysis of full ROC curves. Diabet Med 2018;35:317–22.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37:S81–90.
American Diabetes Association. Standards of medical care in diabetes 2017. Diabetes Care 2017.
Diabetes Association of Thailand. Clinical practice guideline for diabetes. Bangkok: Diabetes Association of Thailand; 2017.
Sitasuwan T, Lertwattanarak R. Prediction of type 2 diabetes mellitus using fasting plasma glucose and HbA1c levels among individuals with impaired fasting plasma glucose: a cross-sectional study in Thailand. BMJ Open 2020;10:e041269.
Carnevale Schianca GP, Fra GP, Bigliocca M, Mella R, Rossi L, Bartoli E, et al. Oral glucose tolerance test-based calculation identifies different glucose intolerance phenotypes within the impaired fasting glucose range. J Diabetes Investig 2014;5:533–8.
Cosson E, Hamo-Tchatchouang E, Banu I, Nguyen M-T, Chiheb S, Ba H, et al. A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients. Diabetes Metab 2010;36:312–8.
Kim DL, Kim SD, Kim SK, Park S, Song KH. Is an oral glucose tolerance test still valid for diagnosing diabetes mellitus? Diabetes Metab J 2016;40:118–28.
Yu EYT, Wong CKH, Ho SY, Wong SYS, Lam CLK. Can HbA1c replace OGTT for the diagnosis of diabetes mellitus among Chinese patients with impaired fasting glucose? Fam Pract 2015;32:631–8.
Kanda T, Nakamura M, Iwasaki M, Wada M, Kurotobi M, Shimizu Y. Clinical significance of HbA1c, serum fructosamine and 1, 5-AG in diabetic patients complicated with liver cirrhosis. J Jpn Diabetes Soc 1993;36:847–54.
Tsutomu Nishida. Diagnosis and clinical implications of diabetes in liver cirrhosis: a focus on the oral glucose tolerance test. J Endocr Soc 2017:886-96.
Imano E, Kanda T, Nakatani Y, Motomura M, Arai K, Matsuhisa M, et al. Impaired splanchnic and peripheral glucose uptake in liver cirrhosis. J Hepatol 1999;31:469–73.
Cacciatore L, Cozzolino G, Giardina MG, De Marco F, Sacca L, Esposito P, et al. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res 1988;7:185–8.
Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Dalla Man C, et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 2004;53:3048–56.
Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990;8:29–36.
Buzzelli G, Chiarantini E, Cotrozzi G, Relli P, Matassi L, Romanelli R G, et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver 1988;8:354–9.
Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967;2:1051–6.
Imano E, Nishida T, Shibata M, Kanda T. Significance of oral glucose tolerance test for the diagnosis of diabetes mellitus in patients with liver cirrhosis. Intern Med 1999;38:918.
White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008;49:831-44.
Pratumvinit B, Reesukumal K, Hanyongyuth S. Hemoglobin A1c levels are slightly but significantly lower in normoglycemic subjects with the hemoglobin E phenotype. Ann Lab Med 2019;39:209–13.
Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012;18:1642–51.
Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Author and Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
